search

Medical & Bio Decision (MBD) provides a 3D cell culture platform specialised in anticancer drug sensitivity. The company’s relationship with Luxembourg started in 2017 when it first sold its medical devices to a hospital here. An invitation to participate in a collaborative research project with a French research centre and the Luxembourg Institute of Health then spurred on discussions regarding longer-term research cooperation.

Exploring Luxembourg

“MBD initially considered locating its European office in France or Germany since it has several customers there,” explains Younhee Kim, Executive Director of the Luxembourg Trade and Investment Office (LTIO) in Seoul, who has supported the company throughout the process. “However, the contacts with the CEO of LIH and Dr Yong-Jun Kwon, who heads the Early Drug Discovery Platform of the Personalized Drug Discovery research group at the LIH Department of Oncology, were instrumental in increasing the company interest to set up an office in Luxembourg.”

The LTIO provided MBD with tailor-made information on the Luxembourg business environment and company incorporation process, as well as on topics such as taxation, the education system and the cost of living. Together with the Ministry of the Economy and the House of Entrepreneurship, the LTIO also helped the MBD management meet with start-up incubators and relevant healthtech players during a visit to Luxembourg in February 2020.

Translational oncology research

MBD announced its decision to set up a joint laboratory with LIH in December 2020. “We selected LIH as our business partner because the institute understands MBD’s technology and vision very well since we have been working with the CEO and with Dr Kwon for a long time,” comments MBD’s CEO Bosung Ku.

The laboratory, which is located at the premises of IBBL in Dudelange in the south of the country, will focus on performing translational oncology research. LIH explains that the 3D cell culture chip developed by MBD makes it possible to identify the most effective anticancer drug using cancer cells derived directly from patients. This innovative three-dimensional solution overcomes some of the issues associated with 2D cultures by providing a more accurate and physiologically relevant tissue model, thereby enabling a more precise prediction of a drug’s efficacy and toxicity profile and supporting next-generation drug screening and development.

Our collaboration will advance precision oncology for the benefit of patients in Luxembourg, Europe and worldwide.

The lab will use samples from cancer patients across Europe and will leverage IBBL’s state-of-the-art biological sample storage facilities. “Our collaboration will advance precision oncology for the benefit of patients in Luxembourg, Europe and worldwide”, explains Dr Kwon.

European expansion

MBD considers the Grand Duchy as an ideal place to grow. “Luxembourg has a favourable business environment and is geographically in the centre of Europe,” comments Mr Ku. “I think it is a very good location for attracting highly skilled staff from France and Germany.”

Luxembourg has a favourable business environment and is geographically in the centre of Europe.

With the MBD-LIH joint lab up and running, the company is now also planning to benefit from its Luxembourg branch to increase its business reach. “We would like to expand our promotion and network throughout Europe and well beyond,” says Mr Ku.

Read more

Building skills for the metaverse

29-06-2022

The integrated 3D virtual worlds commonly called the metaverse might well revolutionise the way we do business. Luxembourg Trade & Invest discussed the needs to build the right skills and the timeframe for adopting the metaverse with the CEO of leading metaverse company Infinite Reality, John Acunto.
Read more

Boosting public-private R&D

28-06-2022

Stimulating innovation and research partnerships is becoming a key priority for Luxembourg R&D funding. Companies cooperating with research centres can receive an additional financial injection, and sector-related calls stimulate public-private partnerships using Luxembourg as a testbed for innovative products.
Read more

A Luxembourg testbed for optimising electrical vehicle fleet charging

27-06-2022

German start-up RiDERgy provides companies with innovative tools for electrifying their vehicle fleet and optimising electric vehicle charging. The company has chosen Luxembourg as the testbed for perfecting and commercialising its offering.
Read more

Developing technology for industry

24-06-2022

Supporting businesses with their R&D projects and helping them speed up prototyping and market introduction is central for the Luxembourg Institute of Science and Technology (LIST). LIST’s Sustainable Biotech Innovation Centre cooperates with companies on their development of bio-based products and bioprocesses.
Read more

Industry-oriented research: the synergy approach

21-06-2022

Performing research in close collaboration with companies is essential for Luxembourg’s research institutes. We spoke to Professor Djamila Aouada at the University of Luxembourg about how the expertise of her team can support industry and their motivation to work in partnership with the private sector.
Read more

All news

Close